Blood test may predict which cancer patients benefit from immunotherapy
NCT ID NCT07485114
Summary
This study aims to find out if measuring a protein called Galectin-3 in the blood can help predict how patients with certain cancers will respond to immunotherapy drugs (PD-1/PD-L1 inhibitors). Researchers will observe 300 adults with kidney, lung, liver, or bladder cancer who are starting this type of treatment. The goal is to see if Galectin-3 levels are linked to treatment success, side effects, and survival, which could help guide future care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tel Aviv Sourasky Medical Center
RECRUITINGTel Aviv, Israel, 64239, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.